Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NvfiledCriticalJanssen Pharmaceutica Nv
Priority claimed from PCT/IB2014/002868external-prioritypatent/WO2015097536A2/en
Publication of CR20160339ApublicationCriticalpatent/CR20160339A/en
La presente invención se refiere a nuevos anticuerpos y fragmentos que se unen al dominio V de la Ig supresora de la activación de linfocitos T (VISTA), y métodos para preparar y usar los mismos. Los métodos de uso incluyen métodos de tratamiento del cáncer, incluyendo leucemias, linfomas, tumores sólidos y melanomas.The present invention relates to new antibodies and fragments that bind to the V domain of the T-cell activation suppressor Ig (VISTA), and methods for preparing and using them. Methods of use include methods of cancer treatment, including leukemia, lymphomas, solid tumors and melanomas.
CR20160339A2013-12-242014-12-22
ANTI-VISTA ANTIBODIES AND FRAGMENTS
CR20160339A
(en)
Composition of 6 mRNA coding for 5t4 (tpbg, survivin (birc5), ny-eso-1 (ctag1b), mage-c1, mage-c2 and muc1 and vaccine to make a useful medication to treat lung cancer